Purchase Order 75F40120P00616
Award Date 9/8/20
Potential Completion Date 9/7/21
Potential Value $94K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Los Angeles, CA 91325, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a firm-fixed-price purchase order awarded by the Department of Health and Human Services Food and Drug Administration to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of human induced pluripotent stem cell-derived cells. The $26,680 contract is to provide specialized cell cultures, including cardiomyocytes, neurons, astrocytes, and hepatocytes, to support the FDA's active research program. The award has no set-aside designation and is a sole-source award,...
- This is a firm-fixed-price contract award to Charles River Laboratories, Inc. (Charles River) by the Department of Health and Human Services (HHS) Food and Drug Administration (FDA) for embryo cryopreservation services. The total contract value is $10,115.20, with a potential value of $8,085.84. The contract has an award date of August 13, 2021, and a completion date of August 15, 2022. This contract is not set aside for a specific business type. Charles River, a global company that provides...
- The U.S. Food and Drug Administration (FDA) awarded a $47,470.00 firm-fixed price purchase order contract to Stemexpress, LLC (doing business as CGT Global), a small disadvantaged woman-owned business, to provide human donor blood for the development of bioassays using peripheral blood mononuclear cells (PBMC) and/or isolated immune cells. The contract has an ultimate completion date of August 31, 2025 and does not utilize a set-aside. Stemexpress, a provider of human biological samples, has...
- The U.S. Food and Drug Administration (FDA), through its National Center for Toxicological Research (NCTR), awarded a $24,895.00 firm-fixed-price purchase order to Fujifilm Cellular Dynamics, Inc. for the supply of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (hiPSC-CMs), also referred to as "iCell Macrophages" from lot #106775. This sole-source procurement was conducted under the authority of FAR 13.106-1(b)(1) to support an approved scientific study (S00913) focused...
- Charles River Laboratories, Inc. has been awarded a firm fixed price contract valued at thirty-one thousand eight hundred fifty-three dollars and forty cents ($31,853.40) by the Department of Health and Human Services' Food and Drug Administration to provide sperm cryopreservation services. The contract has no set-aside designation and work is to be completed by September 7, 2024 at the place of performance in Wilmington, Massachusetts. As a prime contractor, Charles River Laboratories...
- This federal contract award to Charles River Laboratories, Inc., doing business as Charles River, is for $36,468.00 to provide embryo cryopreservation and special air freight services to the Food and Drug Administration (FDA), a civilian agency. The award is a Blanket Purchase Agreement (BPA) call with a firm fixed price. Charles River is a leading provider of research models, preclinical and clinical laboratory services, and cellular products to government agencies. This contract supports the...
- This is a $99,500.00 firm-fixed-price purchase order contract awarded by the Food and Drug Administration (FDA), a civilian agency within the U.S. Department of Health and Human Services, to Fujifilm Cellular Dynamics, Inc., a foreign-owned, for-profit manufacturer of induced pluripotent stem cell-derived human cell lines. The contract is for the supply of iCell Cardiomyocytes, a specialized cell product used in biomedical research, drug development, and toxicology screening. The contract has...
- The U.S. Food and Drug Administration (FDA) awarded a $98,725.00 firm fixed-price purchase order to Fujifilm Cellular Dynamics, Inc. (FCDI), a foreign-owned, for-profit manufacturer of biologically relevant human cells derived from induced pluripotent stem cells (iPSCs). The contract is for the purchase of cardiomyocytes, which are heart muscle cells, and does not have a set-aside designation. FCDI is a key supplier of specialized cell products, particularly to the Department of Health and Human...
- The Department of Health and Human Services National Institutes of Health Clinical Center awarded a $103,103.00 firm fixed-price purchase order contract to Cellgenix USA, a division of Cellgenix GMBH, a for-profit manufacturer of goods. The contract, which had no set-aside designation, is for the provision of specialized cell therapy-related pharmaceuticals such as FLT-3L, SCF, TPO, GM-CSF, interleukin-4, and other cell therapy reagents to support federal cell and gene therapy research...
- This federal contract award is to Charles River Laboratories, Inc., a global contract research organization, for the provision of essential products and services to support pharmaceutical, biotechnology, and government research and development efforts. The $2,097,037.00 firm fixed-price delivery order contract was awarded by the National Human Genome Research Institute, a civilian agency, and has an ultimate completion date of August 31, 2025. The contract does not have a set-aside...